1. KIR3DL2 MUTATION MAY DEFINE A HIGH RATE OF RESPONSE OF AITL TO TIPIFARNIB. (12th June 2019) Authors: Gualberto, A.; Scholz, C.; Mishra, V.; Kessler, L.; Rodriguez, M.; Piris, M.; Witzig, T. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 204 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1096: TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA. (23rd June 2022) Authors: Bock, A.; Poonsombudlert, K.; Larson, M.; Gile, J.; Tawfiq, R.; Maliske, S.; Maurer, M.; Cerhan, J.; Andrade-gonzalez, X.; Saliba, A.; Paludo, J.; Inwards, D.; Ansell, S.; Witzig, T.; Habermann, T.; Link, B.; Ayyappan, S.; Nowakowski, G.; Farooq, U.; Wang, Y. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 986 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P1168: CHARACTERISTICS PREDICTIVE OF PROGRESSION DURING FRONTLINE TREATMENT IN AGGRESSIVE B-CELL LYMPHOMAS. (23rd June 2022) Authors: Bock, A.; Mwangi, R.; Maurer, M.; Cerhan, J.; Ng, W. L.; King, R.; Bennani, N. N.; Ansell, S.; Habermann, T.; Witzig, T.; Wang, Y.; Nowakowski, G. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1054 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PRELIMINARY RESULTS FROM AN OPEN‐LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMA. (June 2017) Authors: Witzig, T.; Sokol, L.; Jacobsen, E.; Advani, R.; Mondejar, R.; Piris, M.; Burrows, F.; Melvin, C.; Mishra, V.; Scholz, C.; Gualberto, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T‐CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T‐CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM A PHASE 2 STUDY. (12th June 2019) Authors: Witzig, T.; Sokol, L.; Kim, W.; Foss, F.; Jacobsen, E.; de la Cruz Vincente, F.; Caballero, D.; Advani, R.; Roncero Vidal, J.M.; Marin‐Niebla, A.; Rodriguez Izquierdo, A.; de Ona Navarrete, R.; Terol, M.J.; Domingo‐Domenech, E.; Rodriguez, M.; Piris, M.A.; Bolognese, J.; Janes, M.R.; Burrows, F.;... Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗